Search Article Keyword:  

 PubMed Submission Abstract PDF  Cover Contents Editorial Board Count: 2317 Download Count: 468 

ISSN 1007-9327 CN 14-1219/R  World J Gastroenterol  2009 May 28; 15(20): 2472-2478


Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies

Massimo C Fantini, Francesco Pallone, Giovanni Monteleone

Massimo C Fantini, Francesco Pallone, Giovanni Monteleone, Department of Internal Medicine, University of Rome “Tor Vergata”, Rome 00133, Italy

Author contributions: Fantini MC wrote the manuscript, Pallone F and Monteleone G contributed to the discussion.

Correspondence to: Massimo C Fantini, MD, PhD, Department of Internal Medicine, University of Rome “Tor Vergata”, Via Montpellier 1, Rome 00133, Italy.

Telephone: +39-6-72596158  Fax: +39-6-72596391

Received: February 2, 2009   Revised: March 23, 2009

Accepted: March 30, 2009

Published online: May 28, 2009



Spondyloarthropathies (SpA) are commonly observed extra-intestinal manifestations of both Crohn’s disease (CD) and ulcerative colitis (UC), the two major forms of inflammatory bowel diseases (IBD). However, the immunological link between these two clinical entities is still poorly understood. Several lines of evidence indicate that SpA may originate from the relocation to the joints of the immune process primarily induced in the gut. The transfer of the intestinal inflammatory process into the joints implicates that immune cells activated in the gut-draining lymph nodes can localize, at a certain point of the intestinal disease, either into the gut or into the joints. This is indicated by the overlapping expression of adhesion molecules observed on the surface of intestinal and synovial endothelial cells during inflammation. Moreover bacterial antigens and HLA-B27 expression may be implicated in the reactivation of T cells at the articular level. Finally, accumulating evidence indicates that a T helper 17 cell-mediated immune response may contribute to IBD and IBD-related SpA with a crucial role played by tumor necrosis factor-a in CD and to a lesser extent in UC.


© 2009 The WJG Press and Baishideng. All rights reserved.


Key words: Cell adhesion molecules; Antigens; Th17; Helper T-cells; Tumor necrosis factor-a


Peer reviewers: Elke Cario, MD, Division of Gastroenterology and Hepatology, University Hospital of Essen, Institutsgruppe I, Virchowstr. 171, Essen D-45147, Germany; Emiko Mizoguchi, MD, PhD, Department of Medicine, Gastrointestinal Unit, GRJ 702, Massachusetts General Hospital, Boston, MA 02114, United States


Fantini MC, Pallone F, Monteleone G. Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies. World J Gastroenterol 2009; 15(20): 2472-2478  Available from: URL:  DOI:



The term spondyloarthropathy (SpA) indicates a group of related diseases, including ankylosing spondylitis (AS), reactive and psoriatic arthritis (ReA and PsA), and undifferentiated spondyloarthritis (uSpA). All these forms of SpA share common clinical features which are sacroiliitis, inflammatory low back pain and oligoarticular asymmetric synovitis. SpA is a frequently observed extraintestinal manifestation in Crohns disease (CD) and ulcerative colitis (UC), the two major forms of inflammatory bowel diseases (IBD). Indeed, the prevalence of SpA associated with CD and UC was 45.7% and 9.9%, respectively in a recent series[1]. Moreover a subtle gut inflammation is present in 25%-75% of patients with documented SpA[2], depending on the subtype, and among these, 6%-13% may evolve to overt IBD, suggesting common pathogenetic mechanisms between these two clinical entities[3-5].

The observation that SpA may occur during IBD has led to the hypothesis that IBD-related SpA originates from extraintestinal spreading of the immunologic process originating in the gut. Results from several studies suggest that the activation of the intestinal immune system may indeed lead, in certain conditions, to the generation of T cell clones which leave the gut compartment to home into the joints. These T cell clones would be able to replicate, in this site, the inflammatory process observed in the gut. However, to render this model plausible some conditions need to be met. Indeed the idea that joint inflammation is driven by T cell clones originating in the gut implies that these cells are able to leave the gut and to transfer into the joints. Secondly, gut-derived T cells need to encounter in the joint environment an adequate antigenic stimulus to allow the reactivation of these cells. Finally, the immune response shaped in the gut must be responsible for the inflammation-related tissue damage observed in SpA.



A critical point for transfer of the inflammatory process from the gut to the joints is the possibility of redirecting the tissue-specific homing of inflammatory cells, mainly T cells, into the synovial compartment. In IBD, the abnormal reactivity of T cells against harmless antigens expressed by the commensal flora is thought to cause chronic intestinal inflammation[6,7]. In the gut-associated lymphoid tissue (i.e. Peyer’s patches and lymphoid follicles) and mesenteric lymph nodes, professional antigen presenting cells (i.e. dendritic cells, DC) migrate from the intestinal lamina propria, prime naïve T cells which in turn differentiate into specialized T helper cells (e.g. Th1, Th2, Th17), thus acquiring the capacity to sustain a specific immune response. The profound changes observed in differentiated T cells in the secondary lymphoid organs include the expression of cell surface adhesion molecules and chemokine receptors which are responsible for the gut-specific T cell homing. Indeed, T cells activated in the Peyers patches and mesenteric lymph nodes express the gut-addressing integrin a4/b7 and the chemokine receptor CCR9[8]. Once activated, these cells reach the bloodstream through the efferent lymphatics and the thoracic duct. In the gut mucosa, the interaction between a4/b7 integrin and its ligand, the mucosal addressin cell adhesion molecule 1 (MadCAM-1) expressed on the venular endothelial sheet[9,10] causes the initial rolling and subsequent arrest of activated T cells. MadCAM-1 is normally expressed on the intestinal mucosa and its expression is further enhanced during inflammation[11]. Once arrested on the surface of the intestinal venules, activated T cells transmigrate through the endothelial layer and move into the lamina propria following the gradient formed by the CCR-9-specific ligand CCL-25[12,13]. Therefore, the specific interaction between a4/b7 integrin with MadCAM-1 and CCR9 with CCL-25 is pivotal for T cell homing into the gut. However it is worth noting that other molecules mediate the cell-to-cell interaction in this process. For instance CD44, the very late antigen-4 (VLA-4, a4b1) and the lymphocytes function associated antigen-1 (LFA-1, aLb2) expressed by activated T cells play a role in the recruitment of T cells into the gut. Moreover the expression of the vascular activated peptide-1 (VAP-1), intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and different subgroups of selectins (i.e. P- and E-selectins) which bind P-selectin glycoprotein-1 (PSGL-1) on T cells, is enhanced in endothelial cells of the inflamed intestine[14]. However, these molecules are not gut specific and they seem to contribute marginally to the specificity of T cell homing into the intestine. Nevertheless, many lines of evidence indicate that these molecules may be involved in the homing of gut-activated T cells in other organs. Initial studies indicated that lamina propria lymphocytes (LPL) isolated from uninflamed gut were able to bind to uninflamed synovial vessels and that this interaction was critically mediated by CD44, VLA-4 and LFA-1[15]. In contrast, the adherence of lamina propria T cells to inflamed synovial vessels was dependent on VAP-1 and CD44[16]. When LPL were isolated from the inflamed gut of IBD patients, these cells bound more efficiently to synovial vessels than cells isolated from uninflamed gut[17]. This higher affinity could be explained by the observation that, in contrast with cells isolated from uninflamed gut, the binding of small, memory-like, T cells from IBD patients was, in addition to VLA-4, a4b7-dependent, thus indicating a more varied use of adhesion molecules by IBD lamina propria T cells. By contrast, immunoblasts isolated from the lamina propria of IBD patients relied on CD44, LFA-1 and VAP-1 for their adhesion to synovial vessels, similar to immunoblasts from uninflamed gut.

Overall these data indicate that T cells primed in the gut-draining secondary lymphoid organs express a pattern of adhesion molecules that in part are responsible for the intestinal specific homing but that might, in particular conditions, mediate the entrance of activated T cells into extraintestinal compartments such as synovial tissue (Figure 1).



As previously mentioned, intestinal commensal bacteria are thought to sustain intestinal inflammation in IBD. Analogously, IBD-related SpA is thought to depend on the interaction between the host and the gut microbiota. This hypothesis is supported by the observation made in rat models of colitis and colitis-associated SpA. These rats, characterized by the over-expression of human HLA-B27, spontaneously develop intestinal inflammation and SpA. However, these animals did not develop inflammation when grown in germ-free conditions[18]. In contrast, both intestinal inflammation and SpA reappeared when they were transferred to a specific pathogen free environment[19,20], thus indicating that the intestinal and articular inflammatory processes depend on the presence of bacteria into the gut lumen.

Although many attempts to isolate living pathogens from the joint fluid during reactive arthritis failed, the presence of Yersinia enterocolitica-, Salmonella enteritidis- and typhimurium-, Yersinia- and Shigella-related antigens have been detected in the joints of these patients[21-23]. This observation suggests that the enteric antigens may be transported into the joints by monocytes. Accordingly, macrophages from the lamina propria of IBD patients were shown to adhere to the endothelial cells of synovial tissue[17]. It is therefore possible that recirculation of antigen-loaded macrophages may provide the antigenic stimulus necessary to sustain T cell activation and inflammation in the joints.

The crucial role of antigen stimulation in the pathogenesis of IBD-related SpA is also supported by the strong genetic association between SpA and the human leukocyte antigen (HLA) class I B-27 (HLA-B27). HLA-B27 was found in 75%-95% of patients affected by SpA[24,25] and in 25%-78% of IBD patients without SpA who developed this extraintestinal manifestation at a later stage of the disease[26,27]. Despite the strong genetic association, the pathogenetic role of HLA-B27 are still poorly understood. Activation of CD8+ T cells involved in the arthritic process by specific bacterial antigens exposed on HLA-B27 has been proposed[28,29]. Moreover, it has been shown that CD4+ T cells isolated from patients with reactive arthritis are activated by bacterial peptides presented in the context of HLA-B27[30]. These data draw a possible scenario in which activated CD4+ T cells migrate into the joints from the gut, in response to bacterial antigens presented by HLA-B27-expressing macrophages. Not necessarily in contrast with this hypothesis are data demonstrating the homology between HLA-B27 sequences and antigens derived from virus and enterobacteria. Indeed a certain level of antigen mimicry may contribute to the onset and/or maintenance of the inflammatory process initially induced by bacterial antigens. For instance, the nonapeptide, LRRYLENGK, derived from HLA-B27 (residues 168-176) shares the same sequence as peptides from enteric organisms (i.e. Pseudomonas aeruginosa, Klebsiella nitrogenase, Escherichia coli, Bacillus megaterium, Salmonella typhimurium). The same peptides originating from either bacteria or HLA-B27 endogenous turnover can be presented by HLA-B27, determining the activation of the same T cell repertoire[31]. Moreover, a dodecapeptide contained in the intracytoplasmic tail of HLA-B27 shows a strong homology with the sequence contained in the DNA primase of the arthritogenic bacteria Chlamydia trachomatis[32]. This fits well with the observation that high titers of antibodies anti-Saccharomyces cerevisiae (ASCA) and anti-neutrophils (pANCA) antibodies are present in IBD-related SpA[33]. Indeed pANCAs have been shown to cross-react with both neutrophil nuclear membrane and a E. coli proteins[34], while no self-antigens have been so far identified for ASCA. These data indicate that in the presence of HLA-B27 but also independently of this HLA antigen, an immune response initially evoked by a bacterial antigen may be further sustained by the cross-reactivity with self-antigens.

Recently, the process of folding and expression of the HLA-B27 heavy chain has received increasing attention as a potential mechanism involved in the pathogenesis of SpA. Under normal conditions, the peptide-loaded HLA class I heavy chain binds the b2-microglobulin (b2m). This assembling process takes place in the endoplasmic reticulum[35]. The folding process of the HLA-B27 heavy chain is slower than that of other HLA alleles thus leading to the generation of misfolded chains[36]. Misfolded chains are usually removed in the endoplasmic reticulum, but in certain conditions, such as viral infection, they accumulate thus generating a cascade of intracellular events including the activation of the protein BiP, the endoplasmic reticulum-unfolded-protein-response (UPR) and the activation of nuclear factor kB (NFkB) which plays a critical role in the induction of inflammation[37]. In contrast with this theory, it has been recently demonstrated that in HLA-B27 over-expressing rats, which normally develop colitis and SpA, the increased expression of b2m prevented colitis but not SpA[38]. In this study over-expression of b2m caused a reduction of HLA-B27 misfolding and an unfolded protein response, suggesting that HLA-B27 heavy chain misfolding may be critical in the development of colitis but not of SpA. In addition to misfolding, data suggest that HLA-B27 heavy chains preferentially form homodimers which bind immunoglobulin-like receptors expressed on the cell surface of natural killer (NK) cells, T cells and monocytes[39]. However, the actual role played by the interaction between HLA-B27 homodimer and its paired receptor in the inflammatory process is still poorly understood. Finally, data suggest that deposition of b2m, caused by the high dissociation rate between HLA-B27 heavy chain and b2m, occurring within synovial tissue, may lead to the initiation of chronic inflammation[40].



The concept that immune cells, activated in the inflamed gut and migrating into the joints, may be able to reproduce in this tissue a similar immune response, is sustained by the observation that common immunological processes operate at both these sites. Attention has been recently focused on the role of T helper 17 cells (Th17) in IBDs and IBD-related SpA. Th17 cells form a novel class of T helper cells characterized by the expression of the proinflammatory cytokines interleukin (IL)-17A, from which comes the name Th17, IL-17F, IL-22 and TNFa. IL-6 and TGFb have been shown to be crucial for the differentiation of these cells while IL-23, another proinflammatory cytokine, is thought to be important for their maintenance and expansion[41,42]. Several lines of evidence indicate that Th17 cells may play a role in the induction and maintenance of gut inflammation in CD while their role in UC is still uncertain. Indeed, IL-17A and IL-17F are highly expressed in the gut of patients affected by CD, and Th17 cells have been shown to induce intestinal inflammation in different mouse models of colitis[43-46]. Analogously, high expression of IL-17 was found in the synovial fluids of SpA-affected patients and an increased number of circulating Th17 memory-like T cells has been recently reported in these patients[47,48]. An association between Th17 cells and IBD is further supported by the observation that mutations of IL-23 receptor reduce the risk of developing IBD[49] and the same mutations were found to protect against SpA[50]. Although the functional role of IL-23R mutations remains unclear, the fact that IL-23 signaling plays a critical role in the Th17-mediated inflammation, implicates that Th17 cells may represent a common pathogenetic mechanism in both IBD and SpA.

Tumor necrosis factor-a (TNFa) is a proin­flammatory cytokine largely expressed in the lamina propria of patients affected by IBD (mainly CD and to a lesser extent UC), rheumatoid arthritis (RA) and SpA. The role of TNFa in IBD-related SpA has been investigated in the TnfΔARE mouse model which is characterized by the high expression of TNFa. These mice develop a phenotype dominated by IBD-like intestinal inflammation and arthritis thus implicating TNFa as a required factor for the induction of inflammation in both IBD and IBD-related SpA[51]. In this model, intact TNFa signaling in radiation-resistant mesenchymal cells was found to be required for the induction of SpA as shown by the absence of SpA observed in lethally irradiated TNFaRI knockout mice reconstituted with TnfΔARE bone marrow cells[52]. Moreover, selective expression of TNFaRI in intestinal myofibroblasts (IMF) and synovial fibroblasts (SF) was sufficient to re-establish intestinal inflammation and SpA in TnfΔARE-TNFaRI knockout mice. MIF and SF expressed high levels of extracellular matrix-degrading metalloproteinase (MMP)-9 and -3 accompanied by reduced levels of the tissue inhibitor of MMPs-1 (TIMP-1) in response to TNFa stimulation which were in part responsible for the tissue damage observed in both the gut and the joints.



These studies provide a rationale for developing new strategies for the therapy of IBD-related SpA. However, only the neutralization of TNFa has so far found clinical application in the therapy of IBD-related SpA. An early report showed that two patients affected by CD-associated AS refractory to conventional therapy, experienced amelioration of the axial symptoms after anti-TNFa therapy with infliximab 5 mg/kg intravenously[53]. The efficacy of infliximab in the therapy of SpA was later confirmed by two randomized controlled trials. In a first randomized, double-blind trial 40 patients affected by SpA were randomly assigned to receive either infliximab 5 mg/kg (weeks 0, 2, and 6) or placebo. At 12 wk there was a significant improvement of both the BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and BASFI (Bath Ankylosing Spondylitis Functional Index) in the infliximab group in comparison to controls[54]. Similar results were obtained by Braun et al[55] in a randomized, controlled, multicenter trial in which 53% (18 of 34) patients affected by AS treated with infliximab 5 mg/kg (weeks 0, 2, 6) vs 9% (3 of 35) treated with placebo showed a reduction of at least 50% of the BASDAI, BASFI and BASMI (Bath Ankylosing Spondylitis Metrology Index) compared to baseline. However the presence of concomitant IBD in the patients participating in both these trials was unknown. The only trial evaluating the efficacy of anti-TNFa in a cohort of patients affected by CD-related SpA is an open-label study comparing infliximab vs conventional therapy[56]. In this study 21 patients with active SpA were enrolled. Sixteen patients with active CD were treated with infliximab (5 mg/kg) at 0, 2, and 6 wk. If remission was achieved patients were treated with a maintenance dose of 3 mg/kg every 6-8 wk otherwise 5 mg/kg was administered. Eight CD-affected patients were in clinical remission at the beginning of the study. These patients were treated with a dose of 3 mg/kg following the same schedule. Twelve additional patients affected by active CD and SpA underwent conventional therapies. Results from this study showed a significant reduction of the BASDAI and spinal pain in the group treated with infliximab in comparison to patients undergoing conventional therapy. Finally, it has been recently suggested that treatment of SpA with infliximab but not etanercept (another anti-TNFa agent) prevents new onset or flares of IBD[57].

The use of adalimumab, a fully humanized anti-TNFa has achieved similar results. A multicenter, randomized, placebo-controlled, trial aimed at assessing the efficacy and safety of 40 mg adalimumab administered subcutaneously for 12 and 24 wk, found that adalimumab was significantly more effective in inducing ASAS20 (20% response according to the ASsessment in Ankylosing Spondylitis International Working Group criteria) than placebo[58]. Moreover the long term efficacy of adalimumab regimen in the treatment of IBD-related SpA has been recently confirmed in a 2-year follow-up study after the initial treatment[59].



SpA is a common extraintestinal manifestation of IBD. However, the immunological mechanisms linking gut and joint inflammation are still poorly characterized. The observation that in most of the cases intestinal inflammation precedes SpA has led to the hypothesis that the inflammatory process initially localized in the gut may be “relocated” to a different site. Indeed most of the data summarized here support this concept, providing evidence that T cells and monocytes/macrophages activated by gut-related antigens may be able to home in to the synovial tissue as a result of the expression of adhesion molecules which partially overlap with those expressed by endothelial cells in the gut. In synovial tissue, activation of inflammatory cells may be sustained by several mechanisms including the presence of bacterial antigens and/or by the altered expression of HLA-B27. Finally Th17 cells and high expression of TNFa may play a crucial role in the inflammation-related tissue damage in both the gut and the joints by inducing the expression of extracellular matrix metalloproteinases. However, it is important to note that in some cases, SpA has been shown to precede IBD thus indicating that the illustrated mechanism may not be always applicable and that other immunological processes may link gut inflammation to inflammatory processes localized in different extra-intestinal sites.



1      Turkcapar N, Toruner M, Soykan I, Aydintug OT, Cetinkaya H, Duzgun N, Ozden A, Duman M. The prevalence of extraintestinal manifestations and HLA association in patients with inflammatory bowel disease. Rheumatol Int 2006; 26: 663-668   PubMed   DOI

2      Leirisalo-Repo M, Turunen U, Stenman S, Helenius P, Seppala K. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum 1994; 37: 23-31   PubMed   DOI

3      Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, Schatteman L, Gyselbrecht L, Elewaut D. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 1995; 22: 2279-2284   PubMed 

4      Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, Schatteman L, Elewaut D. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol 1995; 22: 2273-2278   PubMed

5      Mielants H, Veys EM, De Vos M, Cuvelier C, Goemaere S, De Clercq L, Schatteman L, Elewaut D. The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol 1995; 22: 2266-2272   PubMed

6      Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434   PubMed   DOI

7      Sartor RB, Muehlbauer M. Microbial host interactions in IBD: implications for pathogenesis and therapy. Curr Gastroenterol Rep 2007; 9: 497-507   PubMed   DOI

8      Campbell DJ, Butcher EC. Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med 2002; 195: 135-141   PubMed   DOI

9      Berlin C, Bargatze RF, Campbell JJ, von Andrian UH, Szabo MC, Hasslen SR, Nelson RD, Berg EL, Erlandsen SL, Butcher EC. alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell 1995; 80: 413-422   PubMed   DOI

10    Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, Weissman IL, Hamann A, Butcher EC. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993; 74: 185-195   PubMed   DOI

11    Souza HS, Elia CC, Spencer J, MacDonald TT. Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut 1999; 45: 856-863   PubMed  

12    Stenstad H, Ericsson A, Johansson-Lindbom B, Svensson M, Marsal J, Mack M, Picarella D, Soler D, Marquez G, Briskin M, Agace WW. Gut-associated lymphoid tissue-primed CD4+ T cells display CCR9-dependent and -independent homing to the small intestine. Blood 2006; 107: 3447-3454   PubMed   DOI

13    Johansson-Lindbom B, Svensson M, Wurbel MA, Malissen B, Marquez G, Agace W. Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J Exp Med 2003; 198: 963-969   PubMed   DOI

14    Salmi M, Jalkanen S. Endothelial ligands and homing of mucosal leukocytes in extraintestinal manifestations of IBD. Inflamm Bowel Dis 1998; 4: 149-156   PubMed   DOI

15    Salmi M, Andrew DP, Butcher EC, Jalkanen S. Dual binding capacity of mucosal immunoblasts to mucosal and synovial endothelium in humans: dissection of the molecular mechanisms. J Exp Med 1995; 181: 137-149   PubMed   DOI

16    Salmi M, Rajala P, Jalkanen S. Homing of mucosal leukocytes to joints. Distinct endothelial ligands in synovium mediate leukocyte-subtype specific adhesion. J Clin Invest 1997; 99: 2165-2172   PubMed   DOI

17    Salmi M, Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. J Immunol 2001; 166: 4650-4657   PubMed 

18    Taurog JD, Richardson JA, Croft JT, Simmons WA, Zhou M, Fernandez-Sueiro JL, Balish E, Hammer RE. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994; 180: 2359-2364   PubMed   DOI

19    Rath HC, Wilson KH, Sartor RB. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. Infect Immun 1999; 67: 2969-2974   PubMed 

20    Rath HC, Herfarth HH, Ikeda JS, Grenther WB, Hamm TE Jr, Balish E, Taurog JD, Hammer RE, Wilson KH, Sartor RB. Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats. J Clin Invest 1996; 98: 945-953   PubMed   DOI

21    Hammer M, Zeidler H, Klimsa S, Heesemann J. Yersinia enterocolitica in the synovial membrane of patients with Yersinia-induced arthritis. Arthritis Rheum 1990; 33: 1795-1800   PubMed   DOI

22    Granfors K, Jalkanen S, Lindberg AA, Maki-Ikola O, von Essen R, Lahesmaa-Rantala R, Isomaki H, Saario R, Arnold WJ, Toivanen A. Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. Lancet 1990; 335: 685-688   PubMed   DOI

23    Granfors K, Jalkanen S, von Essen R, Lahesmaa-Rantala R, Isomaki O, Pekkola-Heino K, Merilahti-Palo R, Saario R, Isomaki H, Toivanen A. Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. N Engl J Med 1989; 320: 216-221   PubMed 

24    Purrmann J, Zeidler H, Bertrams J, Juli E, Cleveland S, Berges W, Gemsa R, Specker C, Reis HE. HLA antigens in ankylosing spondylitis associated with Crohn‘s disease. Increased frequency of the HLA phenotype B27,B44. J Rheumatol 1988; 15: 1658-1661   PubMed 

25    Palm O, Moum B, Ongre A, Gran JT. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol 2002; 29: 511-515   PubMed 

26    de Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J Rheumatol 2000; 27: 2860-2865   PubMed 

27    Steer S, Jones H, Hibbert J, Kondeatis E, Vaughan R, Sanderson J, Gibson T. Low back pain, sacroiliitis, and the relationship with HLA-B27 in Crohn’s disease. J Rheumatol 2003; 30: 518-522   PubMed 

28    Kuon W, Sieper J. Identification of HLA-B27-restricted peptides in reactive arthritis and other spondyloarthropathies: computer algorithms and fluorescent activated cell sorting analysis as tools for hunting of HLA-B27-restricted chlamydial and autologous crossreactive peptides involved in reactive arthritis and ankylosing spondylitis. Rheum Dis Clin North Am 2003; 29: 595-611   PubMed   DOI

29    Mertz AK, Wu P, Sturniolo T, Stoll D, Rudwaleit M, Lauster R, Braun J, Sieper J. Multispecific CD4+ T cell response to a single 12-mer epitope of the immunodominant heat-shock protein 60 of Yersinia enterocolitica in Yersinia-triggered reactive arthritis: overlap with the B27-restricted CD8 epitope, functional properties, and epitope presentation by multiple DR alleles. J Immunol 2000; 164: 1529-1537   PubMed 

30    Thiel A, Wu P, Lauster R, Braun J, Radbruch A, Sieper J. Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. Arthritis Rheum 2000; 43: 2834-2842   PubMed   DOI

31    Scofield RH, Kurien B, Gross T, Warren WL, Harley JB. HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria: implications for spondyloarthropathies. Lancet 1995; 345: 1542-1544   PubMed   DOI

32    Ramos M, Alvarez I, Sesma L, Logean A, Rognan D, Lopez de Castro JA. Molecular mimicry of an HLA-B27-derived ligand of arthritis-linked subtypes with chlamydial proteins. J Biol Chem 2002; 277: 37573-37581   PubMed   DOI

33    Torok HP, Glas J, Gruber R, Brumberger V, Strasser C, Kellner H, Marker-Hermann E, Folwaczny C. Inflammatory bowel disease-specific autoantibodies in HLA-B27-associated spondyloarthropathies: increased prevalence of ASCA and pANCA. Digestion 2004; 70: 49-54   PubMed   DOI

34    Cohavy O, Bruckner D, Gordon LK, Misra R, Wei B, Eggena ME, Targan SR, Braun J. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun 2000; 68: 1542-1548   PubMed   DOI

35    Pamer E, Cresswell P. Mechanisms of MHC class I--restricted antigen processing. Annu Rev Immunol 1998; 16: 323-358   PubMed   DOI

36    Mear JP, Schreiber KL, Munz C, Zhu X, Stevanovic S, Rammensee HG, Rowland-Jones SL, Colbert RA. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol 1999; 163: 6665-6670   PubMed  

37   Pahl HL, Sester M, Burgert HG, Baeuerle PA. Activation of transcription factor NF-kappaB by the adenovirus E3/19K protein requires its ER retention. J Cell Biol 1996; 132: 511-522   PubMed   DOI

38    Tran TM, Dorris ML, Satumtira N, Richardson JA, Hammer RE, Shang J, Taurog JD. Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. Arthritis Rheum 2006; 54: 1317-1327   PubMed   DOI

39    Kollnberger S, Bird LA, Roddis M, Hacquard-Bouder C, Kubagawa H, Bodmer HC, Breban M, McMichael AJ, Bowness P. HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired Ig-like receptors. J Immunol 2004; 173: 1699-1710   PubMed 

40    Uchanska-Ziegler B, Ziegler A. Ankylosing spondylitis: a beta2m-deposition disease? Trends Immunol 2003; 24: 73-76   PubMed   DOI

41    Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-238   PubMed   DOI

42    Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006; 441: 231-234   PubMed   DOI

43    Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, Kleinschek MA, Owyang A, Mattson J, Blumenschein W, Murphy E, Sathe M, Cua DJ, Kastelein RA, Rennick D. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116: 1310-1316   PubMed   DOI

44    Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, Kastelein RA. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007; 132: 2359-2370   PubMed   DOI

45    Fina D, Sarra M, Fantini MC, Rizzo A, Caruso R, Caprioli F, Stolfi C, Cardolini I, Dottori M, Boirivant M, Pallone F, Macdonald TT, Monteleone G. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 2008; 134: 1038-1048   PubMed   DOI

46    Seiderer J, Elben I, Diegelmann J, Glas J, Stallhofer J, Tillack C, Pfennig S, Jurgens M, Schmechel S, Konrad A, Goke B, Ochsenkuhn T, Muller-Myhsok B, Lohse P, Brand S. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm Bowel Dis 2008; 14: 437-445   PubMed   DOI

47    Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2008; 58: 2307-2317   PubMed   DOI

48    Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 2007; 74: 304-305   PubMed   DOI

49    Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314: 1461-1463   PubMed   DOI

50    Rahman P, Inman RD, Gladman DD, Reeve JP, Peddle L, Maksymowych WP. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum 2008; 58: 1020-1025   PubMed   DOI

51    Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999; 10: 387-398   PubMed   DOI

52    Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med 2008; 205: 331-337   PubMed   DOI

53    Van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H. Crohn's disease associated with spon­dyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 2000; 356: 1821-1822   PubMed   DOI

54    Van Den Bosch F, Kruithof E, Baeten D, Herssens A, de Keyser F, Mielants H, Veys EM. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002; 46: 755-765   PubMed   DOI

55    Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sorensen H, Zeidler H, Thriene W, Sieper J. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359: 1187-1193   PubMed   DOI

56    Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G, Del Rosso A, Viscido A, Galletti B, Fazzi M, Tonelli F, Matucci-Cerinic M. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy of inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 2004; 63: 1664-1669   PubMed   DOI

57    Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007; 57: 639-6347   PubMed   DOI

58    van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, Dougados M, Reveille JD, Wong RL, Kupper H, Davis JC Jr. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136-2146   PubMed   DOI

59    van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, Dijkmans BA, Mease PJ, Davis JC Jr. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009; 68: 922-929   PubMed 


S- Editor  Tian L    L- Editor  Cant MR    E- Editor  Ma WH






Reviews Add

Related Articles:
Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies
Combined therapeutic approach: Inflammatory bowel diseases and peripheral or axial arthritis
Non-invasive investigation in patients with inflammatory joint disease
Enteropathic spondyloarthropathy: A common genetic background with inflammatory bowel disease?
Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease